sh-Polypeptide-59 for Hair Regrowth

Evidence Review created on 08/24/2026 using AI4L / Grok 4.5

Also known as: rhPDGF-BB, PDGF-BB, recombinant human platelet-derived growth factor-BB, sh-Polypeptide-59 dimer, becaplermin, PDGFB, platelet-derived growth factor B chain

Motivation

sh-Polypeptide-59 is a laboratory-made copy of a human protein that blood platelets release when tissue is injured. Cosmetic hair serums list it on the ingredient panel, and some clinics apply a concentrated two-chain form of the same protein to the scalp after needling, or as an injection, without drawing blood. It is sold both as a leave-on serum ingredient and as a clinic liquid.

The identical protein has been sold for decades as a prescription wound gel, and more recently as an in-office skin product after laser or radiofrequency treatments. That medical track record is why longevity-oriented adults who already use needling or platelet injections have started adding this named peptide to hair routines, even though human hair-count trials of the isolated ingredient remain scarce.

This review examines whether isolated sh-Polypeptide-59 increases hair density or growth-phase duration, how that claim compares with mixed platelet products, and what the wound-care and aesthetic safety file implies for long-term scalp use.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No Grokipedia article on sh-Polypeptide-59 was found.

Examine

No Examine.com article on sh-Polypeptide-59 was found.

ConsumerLab

No ConsumerLab article on sh-Polypeptide-59 was found.

Systematic Reviews

No systematic reviews or meta-analyses for sh-Polypeptide-59 were found on PubMed as of August 24, 2026.

Neither a systematic review of hair-growth efficacy nor a systematic review of malignancy risk for isolated sh-Polypeptide-59 was identified. Mixed-factor PRP alopecia meta-analyses were excluded because they do not test this ingredient.

Mechanism of Action

sh-Polypeptide-59 is a single-chain recombinant copy of human platelet-derived growth factor B, made in Escherichia coli from a synthetic PDGFB gene. Products often use the disulfide-linked homodimer (PDGF-BB), the same ligand as prescription becaplermin.

PDGF-BB binds PDGF receptor-alpha and PDGF receptor-beta (PDGFR-α and PDGFR-β, cell-surface tyrosine kinases) on mesenchymal cells, including dermal papilla cells (the niche at the follicle base) and hair-follicle dermal stem cells. Receptor activation drives phosphatidylinositol 3-kinase / protein kinase B (PI3K/Akt, a cell-survival pathway) and mitogen-activated protein kinase / extracellular signal-regulated kinase (MAPK/ERK, a proliferation pathway).

In mouse telogen (resting-phase) skin, injected PDGF-AA or PDGF-BB induced anagen (the growth phase) and raised Sonic hedgehog (Shh, a follicle-development signal), Lef-1 (a transcription factor in the Wnt follicle-growth pathway), and Wnt5a (a polarity/growth signal). PDGF-BB expands adult hair-follicle dermal stem cells in culture; deleting PDGFR-α depletes that pool over cycles. Human follicle keratinocytes express both receptors; interleukin-1 beta (IL-1β) and interferon-gamma (IFN-γ), cytokines of catagen (the regression phase), down-regulate PDGF.

Knocking out both mesenchymal PDGF receptors still allowed embryonic follicle induction, so PDGF is not required to start a follicle. PDGF-BB also promotes angiogenesis and collagen deposition, the ulcer-gel actions, which could thicken the connective tissue around follicles or feed fibrosis.

The dimer is about 25 kDa. Intravenous half-life is 2–55 minutes. Topical or injected systemic exposure is usually undetectable. It is not metabolized by cytochrome P450 enzymes (CYP, liver drug-metabolizing proteins); clearance is by receptor binding, matrix capture, and α2-macroglobulin (a plasma protein that binds the ligand).

Historical Context & Evolution

PDGF was identified in the 1970s as a serum mitogen released by platelets. Recombinant PDGF-BB (becaplermin, Regranex) was approved by the U.S. Food and Drug Administration (FDA) in 1997 for diabetic neuropathic ulcers after a phase III trial found higher complete-closure rates versus placebo gel. The same protein later entered a periodontal device (GEM 21S) and an orthopedic fusion graft (Augment).

Hair interest followed receptor mapping in follicle epithelium and Tomita and colleagues’ 2006 mouse injections that switched telogen skin into anagen. PRP clinics then marketed mixed platelet lysates for pattern hair loss; PDGF-BB is one of several factors in those preparations, not a standardized dose.

The cosmetic International Nomenclature of Cosmetic Ingredients (INCI) listed sh-Polypeptide-59 as a skin-conditioning recombinant PDGF-B chain produced in E. coli. Aesthetic manufacturers later sold a four-ingredient topical of water, sodium acetate, hyaluronic acid, and sh-Polypeptide-59 dimer, applied after microneedling and, in some clinics, injected into the scalp without a hair-growth approval.

A boxed warning on becaplermin for cancer mortality after three or more tubes was added in the late 2000s from incomplete claims data, then removed in 2018 after larger matched cohorts did not confirm excess cancer death. That history still shapes caution at known tumor sites. Isolated recombinant PDGF-BB has no dedicated hair-growth approval. Lynch Regenerative Medicine, which now holds the Regranex license and sells the aesthetic dimer, authored much of the recent cosmetic safety writing.

Expected Benefits

High 🟩 🟩 🟩

Closure of chronic diabetic neuropathic ulcers

The identical recombinant PDGF-BB protein, as 0.01% becaplermin gel, raised complete closure of chronic diabetic neuropathic ulcers versus placebo gel in more than one randomized controlled trial (RCT, a study that randomly assigns treatments). Benefit is tissue repair in neuropathic wounds under debridement and offloading, not a hair-count endpoint. It is the only replicated human clinical outcome for this ligand and is why clinics treat the dimer as a regenerative topical after barrier disruption. Those ulcer trials were manufacturer-sponsored (Ortho-McNeil).

Magnitude: Complete ulcer closure 50% with becaplermin 100 μg/g versus 35% with placebo gel over 20 weeks in a 382-person phase III RCT (Wieman et al., 1998); a four-trial combined analysis of 922 people found 50% versus 36% closure for median 1.5 cm² ulcers (Smiell et al., 1999).

Medium 🟩 🟩

Recovery of treated skin after radiofrequency microneedling

A single evaluator-blinded RCT applied 300 μg/mL recombinant PDGF-BB to the face immediately after radiofrequency microneedling and reported better 30-day global aesthetic scores and image-analysis texture versus emollient, with no serious adverse events. The trial enrolled 12 people (8 PDGF-BB, 4 control), measured facial skin rather than hair density, and was run by Lynch Regenerative Medicine, which sells the aesthetic dimer. The finding supports post-needling tissue quality, a use case often paired with scalp application, not hair regrowth itself.

Magnitude: Blinded Clinical Global Aesthetic Improvement Score (a 5-point appearance scale) about one point better at day 30 versus emollient in a 12-person facial RCT (Lynch et al., 2025).

Low 🟩

Speculative 🟨

Hair-cycle re-entry and follicle-stem-cell support

PDGF-BB switches mouse resting follicles into growth phase and expands follicle stem cells in culture. No controlled human hair-count trial of this peptide exists. The basis is mechanistic and animal only.

Benefit-Modifying Factors

Baseline biomarker levels: No circulating PDGF-BB, receptor, ferritin, or thyroid cutoff is shown to change isolated sh-Polypeptide-59 hair response. Follicle inventory and photos are the practical baseline, not a blood panel.
Remaining follicle density: Mouse and stem-cell work implies a living dermal papilla and stem-cell pool. Long-standing bald scalp with empty follicular units has less substrate for a PDGF-BB signal than early thinning.
Needling or barrier disruption: The facial RCT applied PDGF-BB onto freshly needled skin. Intact stratum corneum (the outer skin barrier) limits protein penetration; clinic protocols therefore pair the dimer with microneedling.
Sex and pattern: Androgenetic alopecia (pattern hair loss) differs by sex in distribution and hormone drivers. No sh-Polypeptide-59 trial stratified men and women; Tomita used male mice.
Inflammatory cytokine tone: IL-1β and IFN-γ down-regulate PDGF in cultured human follicle cells, so telogen effluvium (resting-phase shedding) or inflammatory alopecias may blunt the same pathway (Kamp et al., 2003).
Age: PDGFR-α loss depletes the adult follicle dermal stem-cell pool over successive cycles. Older scalps may have fewer cells to recruit, while ulcer-gel data showed no overall efficacy gap above age 65.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: replicated topical rhPDGF-BB trials reported adverse-event rates comparable to placebo gel, and later matched cancer-mortality cohorts did not confirm a lasting excess of cancer deaths.

Medium 🟥 🟥

No risk reaches Medium: human cancer-outcome data are internally conflicting, and remaining topical adverse events are vehicle-matched trial rates or uncontrolled post-marketing reports.

Low 🟥

Malignancy risk ⚠️ Conflicted

Becaplermin drives cell growth and new vessels. Early claims data linked more distant cancers after three or more gel tubes; later matched cohorts did not confirm that signal. Net reading: later matched cohorts did not confirm excess cancer death, but the label still bars use on a known local tumor.

Magnitude: Cancers in 8 of 291 becaplermin-treated trial participants (2.7%) versus 2 of 200 vehicle (1%) over ~20 months, relative risk (ratio of event rates) 2.7 (95% CI, confidence interval 0.6–12.8); a later matched cohort of 1,622 initiators found hazard ratio (relative event rate over time) 1.2 (95% CI 0.7–1.9) for incident cancer and no excess cancer mortality overall (rate ratio, compared event rates over follow-up, 1.0, 95% CI 0.5–2.3) (Ziyadeh et al., 2011; Slade et al., 2025; Regranex prescribing information).

Application-site erythema and burning

Erythematous rash (red skin rash) occurred in 2% of both becaplermin and placebo gel arms, so vehicle is a plausible contributor. Post-marketing reports include burning and erythema. The facial PDGF-BB trial reported no adverse reactions; isolated scalp series were not found.

Magnitude: Erythematous rash in 2% of both becaplermin and placebo gel arms; burning and erythema reported after marketing without a quantified excess over vehicle (Regranex prescribing information; Wieman et al., 1998).

Excess granulation tissue

PDGF-BB stimulates granulation tissue, the intended ulcer-gel action, so excess local healing tissue is a mechanistic concern on disrupted skin. US randomized trials reported adverse-event rates similar to placebo gel and did not isolate a hypergranulation (excess healing tissue) rate. No scalp series exists.

Magnitude: Not quantified in available studies. US ulcer-gel trials matched placebo for overall adverse events and did not report a hypergranulation rate; no scalp series exists (Wieman et al., 1998).

Speculative 🟨

Fibrosis around hair follicles

PDGF-BB stimulates fibroblasts and collagen deposition. Repeated scalp use could theoretically thicken the connective tissue around follicles. No human scalp fibrosis series exists; the basis is mechanistic only.

Risk-Modifying Factors

Known local neoplasm: Label contraindication for becaplermin at tumor sites. A proliferative, angiogenic protein on or into a lesion is the principal theoretical hazard.
Prior malignancy: Label asks that benefits and risks be weighed in people with known cancer. Distant malignancies were reported; later cohorts did not show a clear excess.
Application volume and duration: The historical mortality signal was confined to three or more 15 g tubes of ulcer gel, i.e., high cumulative topical dose, not a single aesthetic vial.
Sex: No sex-specific rhPDGF-BB toxicity split is established. Pattern hair loss is more often treated in men; ulcer trials enrolled mixed adults.
Age: Ulcer-gel safety was similar above age 65; numbers over 75 were small. Pediatric use under 16 is not established. Barrier and cancer background both change with age.
Baseline blood markers: No circulating PDGF-BB or receptor blood test predicts toxicity. Ulcer-gel safety was not stratified by a pretreatment lab cutoff.
Broken versus intact skin: Needled or ulcerated skin raises local exposure versus leave-on serum on intact scalp, which also changes irritation and, theoretically, systemic absorption.

Key Interactions & Contraindications

Other topicals on the same site (caution): Use with other topical drugs is unstudied. Clinics often stagger minoxidil, corticosteroids (clobetasol, anti-inflammatory steroid creams), or keratolytics (salicylic acid, skin-loosening agents) to avoid stacked irritation.
Angiogenesis inhibitors such as bevacizumab (caution): PDGF-BB recruits vessels. Systemic vessel-blocking cancer drugs (bevacizumab) could blunt local repair; the converse concern is feeding residual tumor vasculature.
Stacked cosmetic growth-factor serums (monitor): Leave-on formulas often combine sh-Polypeptide-59 with other recombinant vessel, fibroblast, and insulin-like growth factors plus copper tripeptide-1. Additive mitogenic load is unquantified.
PRP or concentrated growth factor (monitor): Autologous lysates already contain PDGF-BB. Same-session stacking with recombinant dimer is used in some clinics; extra benefit is unproven and duplicate angiogenic signaling is the interaction.
Immunosuppressants such as cyclosporine or methotrexate (monitor): These drugs dampen immune activity. Wound-gel closure assumes an intact repair cascade; systemic immunosuppression may blunt the fibroblast response PDGF-BB is meant to drive.
Paraben or m-cresol sensitivity (caution): Regranex vehicle can irritate; interruption and patch testing are the labeled next step. Cosmetic dimers use different vehicles (often hyaluronate/acetate).

Populations who should avoid sh-Polypeptide-59:

Known neoplasm at the planned application or injection site (becaplermin contraindication)
Active cutaneous or scalp malignancy, including untreated keratinocyte cancers (common cancers of the outer skin cells) in the field
Documented hypersensitivity to recombinant PDGF-BB or to the product vehicle
Children under 16 years, in whom effectiveness and safety of the related gel are not established
Pregnancy and lactation: no adequate human reproductive data for topical or injected recombinant PDGF-BB

Risk Mitigation Strategies

Site survey before application: Photograph and inspect for undiagnosed lesions. This avoids putting a proliferative protein onto a local neoplasm, the labeled contraindication.
Patch test on intact skin: A 24-hour inner-arm or post-auricular test identifies vehicle or protein contact reactions before full-scalp or post-needling use.
Topical rather than unapproved injection: Clinic scalp injection of aesthetic dimer is not an FDA-cleared route. Topical use on needled skin stays closer to studied local exposure.
Limit cumulative high-dose gel: The historical cancer-mortality signal was in people dispensed three or more 15 g ulcer-gel tubes. Aesthetic vial counts are far lower; tracking sessions still bounds dose.
Single-use product on open skin: Needling plus a multi-use cosmetic bottle can inflame the field. Single-use sterile dimer and skipping application onto inflamed scalp reduce that application-site load.
Stop for persistent erythema or nodules: Ongoing redness, burning, or excess granulation is the labeled reason to interrupt and reassess, including patch testing.

Therapeutic Protocol

Two marketed patterns: Daily leave-on cosmetic serums list sh-Polypeptide-59 among many peptides at undisclosed dose. In-office aesthetic dimer is applied after microneedling, typically every 4–6 weeks for 3–4 sessions, then maintenance.
In-office concentration used in a trial: Lynch et al. spread up to 1.0 mL of 300 μg/mL recombinant PDGF-BB on freshly needled facial skin. Scalp clinics copy that topical-after-needling pattern without a hair RCT.
Time of day: Leave-on serums are used on clean, dry scalp, often at night to cut wash-off. In-office product is applied immediately after needling, not on a clock.
Half-life and splitting: Intravenous half-life is 2–55 minutes; topical systemic levels are usually undetectable. The protein is not split into multiple daily doses; ulcer gel was once daily.
Genetics: No PDGFR or PDGFB variant is used to choose a hair dose. Androgen-receptor and 5-alpha-reductase (the enzyme that makes dihydrotestosterone) status shape pattern hair loss, not this peptide.
Sex: No sex-specific recombinant PDGF-BB hair dose exists. Female-pattern thinning and male vertex/temple loss are treated with the same topical or needling schedules in clinic menus.
Age: Protocols are described for adults. Ulcer-gel data included people 65 and over without a dose change; use under 16 is not established.
Baseline follicle inventory: Clinics that photograph and use trichoscopy (scalp microscopy) first can see whether miniaturized units remain. Empty scalp is a poor substrate in the animal literature.
Competing approaches: Isolated dimer versus autologous PRP versus minoxidil/finasteride. None is a default; PRP is mixed-factor and hormone drugs have a separate evidence base.
Pre-existing disease: Scarring alopecias, active infection, and keloid tendency (overgrown scar tissue) change the risk/benefit of a fibroblast mitogen plus needling. Those conditions are screened out in careful practices.

Discontinuation & Cycling

Duration of use: Cosmetic serums are sold as ongoing leave-on care. In-office dimer is a course plus maintenance, not a one-time lifetime implant.
Withdrawal: No withdrawal syndrome is described for topical or local recombinant PDGF-BB. Any hair that depended on a transient anagen signal would be expected to cycle out after the signal stops, as with other growth-phase tools.
Taper: Ulcer gel is stopped when the wound closes or when size has not fallen about 30% by 10 weeks. No taper is specified for aesthetic dimer or hair serums.
Cycling: No evidence that scheduled time off preserves PDGFR sensitivity on the scalp. Some clinics space maintenance to quarterly sessions for cost and cumulative-dose reasons, not proven receptor reset.
Return of thinning: If anagen re-entry is real in humans, stopping would likely allow telogen to return on the person’s usual schedule. That reversal has not been measured for isolated sh-Polypeptide-59.

Sourcing and Quality

INCI identity: Matching listings use SH-POLYPEPTIDE-59 (single-chain recombinant PDGF-B from E. coli). The clinic dimer is often listed as sh-Polypeptide-59 dimer (PDGF-BB).
Monomer versus dimer: Biologically active PDGF-BB is a disulfide-linked homodimer of about 25 kDa. A cosmetic listing of the single chain does not prove dimer content or receptor-level dose.
Host and impurities: Regranex is produced in Saccharomyces cerevisiae; many INCI descriptions use E. coli. Host-cell protein, endotoxin, and folding differ; third-party certificates are uncommon on serums.
Concentration disclosure: The facial RCT used 300 μg/mL. Leave-on serums almost never state micrograms per milliliter. A named peptide near the bottom of an ingredient list is not a clinical dose.
Cold chain: Recombinant PDGF-BB gel is stored refrigerated (2–8°C) and not frozen. Room-temperature cosmetic bottles are convenient but unproven for this protein’s activity.
Reputable supply: Prescription becaplermin gel is the regulated drug form. Aesthetic dimer is sold to clinics (e.g., Ariessence Pure PDGF+). Consumer serums (including multi-peptide hair drops) are cosmetics, not equivalent to the drug.

Practical Considerations

Time to effect: Hair-cycle tools are generally judged at 3–6 months. Mouse anagen induction was immediate at injection sites; no human timeline exists for isolated sh-Polypeptide-59 density.
Common pitfalls: Treating empty bald scalp; expecting PRP-level results from a leave-on serum; injecting a topical cosmetic; stacking every growth-factor peptide at once; skipping lesion checks.
Regulatory status: Cosmetic INCI use is topical and not a hair-loss drug claim. Becaplermin is FDA-approved only for specified diabetic ulcers. Scalp injection of aesthetic dimer is off-label and not an approved drug procedure.
Cost and access: In-office PDGF-BB sessions typically cost hundreds of dollars per visit without insurance for hair, while payers more often cover inexpensive minoxidil or finasteride, a financial incentive that can bias guidelines toward those drugs. Leave-on serums cost less but have unknown dose.

Interaction with Foundational Habits

Sleep: Direction indirect. No effect of topical or local PDGF-BB on sleep architecture is described. Poor sleep can raise telogen shedding, a competing drag on any growth-phase signal.
Nutrition: Direction none on nutrient stores. The peptide does not deplete nutrients. Hair-shaft production still needs protein, iron, and energy; a mitogen on a nutrient-restricted follicle has little substrate.
Exercise: Direction none known. Endurance work releases platelet-derived signals systemically, which is not a substitute for scalp PDGF-BB and is not shown to blunt or strengthen topical dimer. No timing versus workouts is established.
Stress management: Direction indirect and blunting. Psychological and physiologic stress can trigger telogen effluvium via cortisol and cytokines (including IL-1β), which down-regulate follicular PDGF.

Monitoring Protocol & Defining Success

Baseline work is photographic and trichoscopic, not a blood panel. Before the first serum or in-office dimer session, matched vertex and temple photographs plus trichoscopy of marked sites record density, shaft diameter, and vellus-to-terminal mix (fine versus thick hairs). A full-scalp lesion check is the safety screen that matches the neoplasm contraindication. Blood tests are not required to start topical sh-Polypeptide-59; they are added only when another hair drug already needs them.

Ongoing checks use the same photos and trichoscopy at about 12 weeks, 24 weeks, then every 6–12 months if use continues. Success is a rise in hairs per square centimeter or shaft diameter versus that person’s baseline, not a population lab range. Persistent erythema, nodules, or new lesions prompt stopping. No circulating PDGF-BB assay is used to titrate dose, because systemic levels after local use are usually undetectable.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Hair density (trichoscopy, hairs/cm²)	No established target; track change from the individual’s own mapped-site baseline	Primary hair-regrowth endpoint	Same sites, device, and hair length; conventional labs have no density range
Hair shaft diameter (μm)	No established target; track change from own baseline	Miniaturization versus thickening	Pair with density; PRP literature sometimes links PDGF-BB content to caliber, not isolated peptide
Vellus-to-terminal ratio	Shift toward terminal versus that person’s baseline	Marks real follicle recovery rather than persistent vellus hair	Read with photographs; lighting artifacts are common
Daily shed count (collected hairs)	Fall versus that person’s pre-treatment average	Early shedding signal	Uncontrolled and season-sensitive; use as a trend, not a lab
Application-site skin exam	Intact skin without new papules, ulcers, or suspected tumors	Catches irritation and lesions	Repeat at each in-office visit; biopsy unexplained growths before more PDGF-BB

Qualitative markers:

New hairs at the hairline or vertex on matched photographs
Reduced visible scalp through the part
Scalp comfort versus burning or tightness after application
No new nodules or non-healing spots in the treated field

Emerging Research

Missing hair RCTs: No ClinicalTrials.gov study of becaplermin, rhPDGF-BB, Ariessence, or sh-Polypeptide-59 lists alopecia as a condition. Independent, pre-registered scalp density trials would be the result that could most change the hair case, in either direction.
Post-laser Ariessence trial: A recruiting 21-person randomized post-market study applies Ariessence Pure PDGF+ after facial ablative laser versus emollient (NCT07718347). It is not a hair-count trial; a positive or null appearance result would still tighten or weaken the post-injury extrapolation used on scalps.
Facial needling signal: A 12-person manufacturer-run facial trial found better 30-day appearance after PDGF-BB on radiofrequency-needled skin (Lynch et al., 2025). An independent scalp replication with hair counts could support or shrink that extrapolation.
Developmental versus adult niche: Mesenchymal PDGF receptors were dispensable for embryonic follicle formation (Rezza et al., 2015), against adult stem-cell dependence (González et al., 2017). Further lineage work could weaken the adult-scalp rationale.
PRP is not a proxy: PRP alopecia meta-analyses mix many platelet factors (Zhang et al., 2023). Head-to-head recombinant PDGF-BB versus PRP would show whether this ligand carries or falls short of mixed lysates.
Residual malignancy file: Manufacturer-linked reviews argue the boxed warning was a false signal (Hee et al., 2026; Slade et al., 2025). Independent long-term scalp-injection cohorts would tighten or reopen that risk.

Conclusion

sh-Polypeptide-59 is a laboratory-made copy of human platelet-derived growth factor B, usually sold as the active two-chain form. The hair case rests on mouse growth-phase switching and stem-cell culture, not on controlled human hair-count trials of the isolated peptide. Mixed platelet injections, which contain this protein among many others, are a separate evidence pile and do not show that this single ingredient regrows hair.

The same protein has a long wound-gel record: more complete closure of diabetic neuropathic ulcers in more than one randomized trial, and adverse-event rates close to placebo gel. Those ulcer trials were manufacturer-sponsored (Ortho-McNeil). A later cancer-death warning was added, then removed after larger matched follow-up did not show a lasting excess of cancer deaths. The current label still treats known tumor at the application site as a reason not to use it, and distant cancers have been reported. Much of the recent aesthetic promotion comes from Lynch Regenerative Medicine, now selling both the wound gel and the cosmetic two-chain product, financial interests to weigh when reading clinic claims.

For adults optimizing hair, this ingredient is a well-characterized local signaling protein with strong tissue-repair data, a still-theoretical hair-density benefit when used alone, and a safety file that is large for topical wound use and thin for repeated scalp injection.

Top - Benefits - Risks - Protocol

sh-Polypeptide-59 for Hair Regrowth

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Closure of chronic diabetic neuropathic ulcers

Medium 🟩 🟩

Recovery of treated skin after radiofrequency microneedling

Low 🟩

Speculative 🟨

Hair-cycle re-entry and follicle-stem-cell support

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Malignancy risk ⚠️ Conflicted

Application-site erythema and burning

Excess granulation tissue

Speculative 🟨

Fibrosis around hair follicles

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion